EUACCโ† Back to showcase
LUMINATE MEDICAL LIMITED

LUMINATE MEDICAL LIMITED

Grant-FundedCORDIS

LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss

Visit website
๐Ÿ‡ฎ๐Ÿ‡ช GALWAY, Irelandยทluminatemed.com
Digital Health ยท Robotics
Chemotherapy-induced alopecia (CIA) is hair loss associated with chemotherapy treatment for cancer. LILY is a portable, comfortable, and effective CIA prevention device that uses localised microvasculature compression therapy (LMCT) to prevent CIA. The LILY device uses this unique LMCT technique to reduce perfusion at the scalp and prevent the destructive action of chemotherapy on hair follicles. By applying a consistent low-level pressure (between 35 and 60 mmHg) to the local micro blood vessels, which could deliver chemotherapy drugs to fast-dividing hair follicles, the vessels are temporarily compressed, inhibiting drug delivery. The device comprises a proprietary pneumatic bladder network design and soft robotics system with the ability to non-invasively induce vasoconstriction in superficial vessels of the scalp to mechanically control tissue perfusion, and an electronic control system for both patient management of the system and real-time feedback into the treatment protocol.
EU Grantsโ‚ฌ2.5M
Open to funding
All-time revenueโ€”
MRRPrivateโ€ขโ€ขโ€ขโ€ขโ€ขโ€ข
Founderโ€”
Foundedโ€”
๐Ÿ‡ฎ๐Ÿ‡ชIreland
RevenuePrivate
Revenue data is privateThis company has chosen not to share revenue metrics
Tags:Digital HealthRobotics
Looking for:InvestmentPartnerships
LUMINATE MEDICAL LIMITED โ€” LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss | EUACC